Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
210.45
-8.39 (-3.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
592,714
Open
220.51
Bid (Size)
84.57 (200)
Ask (Size)
245.00 (100)
Prev. Close
218.84
Today's Range
209.56 - 222.55
52wk Range
160.86 - 250.74
Shares Outstanding
57,152,295
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate
↗
May 18, 2026
Via
Chartmill
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
-1.3%
-1.3%
1 Month
-10.8%
-10.8%
3 Month
-12.5%
-12.5%
6 Month
+2.4%
+2.4%
1 Year
+18.5%
+18.5%
More News
Read More
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit
↗
May 09, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q1 2026 Earnings Call Transcript
↗
May 08, 2026
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
Via
MarketMinute
Topics
Economy
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know
↗
March 20, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis (ASND) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Via
The Motley Fool
Topics
Earnings
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum
↗
January 28, 2026
Via
Chartmill
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
A Look Ahead: Ascendis Pharma's Earnings Forecast
↗
November 11, 2025
Via
Benzinga
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript
↗
February 11, 2026
Via
The Motley Fool
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan
↗
December 25, 2025
Via
Chartmill
Why Dyne Therapeutics Stock Was Crushing it This Week
↗
November 21, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
November 19, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Ascendis (ASND) Q3 2025 Earnings Call Transcript
↗
November 13, 2025
Via
The Motley Fool
Topics
Earnings
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
November 12, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
October 29, 2025
Via
Benzinga
Looking Into Ascendis Pharma AS's Recent Short Interest
↗
October 21, 2025
Via
Benzinga
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis
↗
October 14, 2025
Via
Chartmill
What Does the Market Think About Ascendis Pharma AS?
↗
September 29, 2025
Via
Benzinga
Frequently Asked Questions
Is Ascendis Pharma A/S - Ordinary Share publicly traded?
Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - Ordinary Share?
The current price of Ascendis Pharma A/S - Ordinary Share is 210.45
When was Ascendis Pharma A/S - Ordinary Share last traded?
The last trade of Ascendis Pharma A/S - Ordinary Share was at 06/05/26 04:00 PM ET
What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
The market capitalization of Ascendis Pharma A/S - Ordinary Share is 12.03B
How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
Ascendis Pharma A/S - Ordinary Share has 12B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.